Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0902 vs Enbrel in rheumatoid arthritis
CTR20201489Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of etanercept biosimilar QL0902 in rheumatoid arthritis (RA), sponsored by Qilu Pharmaceutical. Started Jul 2020; status: completed.
02
Drugs
etanercept biosimilar QL0902
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20201489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201489.